PDF(Pubmed)
Abstract：
Acneiform eruption is the recognized dermatological side effect of sirolimus, an inhibitor of the mammalian target of rapamycin, although the pathophysiological mechanisms and dose dependency of this side effect remain unclear. This case report describes a case of a 40-year-old Japanese woman treated with systemic sirolimus who developed acneiform eruptions following the administration of clarithromycin. The acneiform eruption resolved after discontinuation of sirolimus and relapsed with the resumption. Since sirolimus and clarithromycin have a potential drug-drug interaction mediated by cytochrome P450 3A (CYP3A), this case suggests that the acneiform eruption developed in association with elevated blood levels of sirolimus. We conclude that clinicians should be aware of the possibility of developing acneiform eruption during sirolimus treatment, especially when administered with medications that inhibit CYP3A.
摘要：
痤疮样爆发是西罗莫司公认的皮肤病学副作用，哺乳动物雷帕霉素靶标的抑制剂，尽管这种副作用的病理生理机制和剂量依赖性仍不清楚。该病例报告描述了一例40岁的日本妇女接受全身西罗莫司治疗，该妇女在服用克拉霉素后出现了痤疮样爆发。停用西罗莫司后，痤疮样爆发得以解决，并随着恢复而复发。由于西罗莫司和克拉霉素具有由细胞色素P4503A（CYP3A）介导的潜在药物相互作用，该病例提示痤疮样爆发与西罗莫司血浓度升高有关。我们得出的结论是，临床医生应该意识到西罗莫司治疗期间发生痤疮样爆发的可能性，特别是当与抑制CYP3A的药物一起给药时。
